Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis

被引:26
|
作者
Skeldal, Sune
Larsen, Jakob V.
Pedersen, Katrine E.
Petersen, Helle H.
Egelund, Rikke
Christensen, Anni
Jensen, Jan K.
Gliemann, Jorgen
Andreasen, Peter A.
机构
[1] Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark
[2] Univ Aarhus, Interdisciplinary Nanosci Ctr iNANO, Aarhus, Denmark
[3] Univ Aarhus, Dept Biochem Med, Aarhus, Denmark
关键词
low-density lipoprotein receptor-related protein; plasminogen activator inhibitor 1; sorting protein-related receptor; urokinase plasminogen activator; very-low-density lipoprotein receptor;
D O I
10.1111/j.1742-4658.2006.05511.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Some endocytosis receptors related to the low-density lipoprotein receptor, including low-density lipoprotein receptor-related protein-1A, very-low-density lipoprotein receptor, and sorting protein-related receptor, bind protease-inhibitor complexes, including urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), and the uPA-PAI-1 complex. The unique capacity of these receptors for high-affinity binding of many structurally unrelated ligands renders mapping of receptor-binding surfaces of serpin and serine protease ligands a special challenge. We have mapped the receptor-binding area of the uPA-PAI-1 complex by site-directed mutagenesis. Substitution of a cluster of basic residues near the 37-loop and 60-loop of uPA reduced the receptor-binding affinity of the uPA-PAI-1 complex approximately twofold. Deletion of the N-terminal growth factor domain of uPA reduced the affinity 2-4-fold, depending on the receptor, and deletion of both the growth factor domain and the kringle reduced the affinity sevenfold. The binding affinity of the uPA-PAI-1 complex to the receptors was greatly reduced by substitution of basic and hydrophobic residues in alpha-helix D and alpha-helix E of PAI-1. The localization of the implicated residues in the 3D structures of uPA and PAI-1 shows that they form a continuous receptor-binding area spanning the serpin as well as the A-chain and the serine protease domain of uPA. Our results suggest that the 10-100-fold higher affinity of the uPA-PAI-1 complex compared with the free components depends on the bonus effect of bringing the binding areas on uPA and PAI-1 together on the same binding entity.
引用
收藏
页码:5143 / 5159
页数:17
相关论文
共 50 条
  • [41] Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 indicate fibrinolysis shut-down in COVID-19
    Yatsenko, T.
    Korolova, D.
    Nalbat, A.
    Rios, R.
    Nogueira, T.
    Shevchuk, O.
    Hattori, K.
    Heissig, B.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2024, 54
  • [42] Plasminogen activator inhibitor-1 partially protects mice against cardiac fibrosis by inhibiting urokinase-type plasminogen activator-mediated plasminogen activation
    Gupta, K. K.
    Donahue, D. L.
    Sandoval-Cooper, M. J.
    Emge, D. J.
    Castellino, F. J.
    Ploplis, V. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 257 - 257
  • [43] Keratinocytes and Head and Neck Squamous Cell Carcinoma Cells Regulate Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Fibroblasts
    Hakelius, Malin
    Koskela, Anita
    Ivarsson, Mikael
    Grenman, Reidar
    Rubin, Kristofer
    Gerdin, Bengt
    Nowinski, Daniel
    ANTICANCER RESEARCH, 2013, 33 (08) : 3113 - 3118
  • [44] Differential expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in early and late gestational mouse skin and skin wounds
    Huang, EY
    Wu, HY
    Island, ER
    Chong, SS
    Warburton, D
    Anderson, KD
    Tuan, TL
    WOUND REPAIR AND REGENERATION, 2002, 10 (06) : 387 - 396
  • [45] Production of Urokinase-Type Plasminogen Activator (u-PA) and Plasminogen Activator Inhibitor-1 (PAI-1) in Human Brain Tumours
    Y. Arai
    T. Kubota
    T. Nakagawa
    M. Kabuto
    K. Sato
    H. Kobayashi
    Acta Neurochirurgica, 1998, 140 : 377 - 386
  • [46] Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1
    Higazi, AAR
    Mazar, A
    Wang, JY
    Reilly, R
    Henkin, J
    Kniss, D
    Cines, D
    BLOOD, 1996, 87 (09) : 3545 - 3549
  • [47] Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours
    Arai, Y
    Kubota, T
    Nakagawa, T
    Kabuto, M
    Sato, K
    Kobayashi, H
    ACTA NEUROCHIRURGICA, 1998, 140 (04) : 377 - 386
  • [48] ELEVATED PLASMINOGEN ACTIVATOR INHIBITOR-1 LEVEL CORRELATES WITH LOW-DENSITY LIPOPROTEIN SUBFRACTIONS IN OBESITY
    Lorincz, H.
    Szentpeteri, A.
    Somodi, S.
    Harangi, M.
    Fulop, P.
    Paragh, G.
    Seres, I.
    ATHEROSCLEROSIS, 2019, 287 : E165 - E165
  • [49] TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND TISSUE-TYPE PLASMINOGEN ACTIVATOR-PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 COMPLEX ARE RECOGNIZED BY DIFFERENT RECEPTOR SYSTEMS IN THE LIVER
    KUIPER, J
    OTTER, M
    VANZONNEVELD, AJ
    RIJKEN, DC
    VANBERKEL, TJC
    CIRCULATION, 1993, 88 (04) : 366 - 366
  • [50] Urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor-1: New functional risk factors in head and neck squamous cell cancer
    Wollenberg, B
    Jan, NV
    Jund, R
    Chaubal, S
    Untch, M
    ONCOLOGY REPORTS, 1997, 4 (04) : 853 - 855